Citius Pharmaceuticals, Inc. Gains (Losses) on Restructuring of Debt
Citius Pharmaceuticals, Inc. (CTXR) reported Gains (Losses) on Restructuring of Debt of $166.56 thousand for the 12-month period ending 2021-09-30, per its 10-K filed 2022-12-22.
Discontinued › Expense Statement › Operating Expenses
us-gaap:GainsLossesOnRestructuringOfDebt · last filed 2022-12-22
- Citius Pharmaceuticals, Inc. gains (losses) on restructuring of debt for fiscal 2021 was $166.56K.
| Period end | Gains (Losses) on Restructuring of Debt 12 month |
|---|---|
| 2021-09-30 | $166.56K 10-K · filed 2022-12-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |